恒瑞医药公告，子公司山东盛迪医药有限公司的HRS-5346片被国家药品监督管理局药品审评中心纳入 突破性治疗品种名单。HRS-5346是一种Lp（a）口服小分子抑制剂，拟用于治疗脂蛋白（a）水平的升 高。目前国内外尚无同类产品获批上市。 ...

智通财经APP讯，恒瑞医药(01276)发布公告，于2026年1月27日该公司斥资人民币1003.86万元回购17.5 万股A股，回购价格为每股人民币57.20-57.48元。 ...

格隆汇1月27日丨恒瑞医药(01276.HK)发布公告，2026年1月27日耗资人民币1003.9万元回购17.5万股A 股，回购价格每股57.2-57.48元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2026年1月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | ...

Group 1 - The Hong Kong IPO market has been thriving since January 2026, with 12 companies successfully listed and raising nearly 35 billion HKD as of January 27, 2026 [1] - UBS and Deloitte China predict that the total financing scale of Hong Kong IPOs in 2026 is expected to exceed 300 billion HKD, indicating a strong recovery in the market [4] - The competitive landscape of the Hong Kong investment banking sector is transforming, with both Chinese and international investment banks actively participating, making it a key driver for growth in intermediary institutions [1][2] Group 2 - In 2025, the top ten equity underwriting positions were evenly split between Chinese and international institutions, with Chinese firms holding six positions after mergers [2] - As of January 27, 2026, Chinese institutions occupy seven of the top ten positions in equity underwriting, commanding over 70% of the market share [2] - The demand for Chinese companies to go global is strong, and Chinese brokers are becoming dominant players in the Hong Kong IPO market [2] Group 3 - Morgan Stanley has emerged as the leading equity financing underwriter in the Asia-Pacific region for 2025, significantly benefiting from the resurgence of Hong Kong equity financing [3] - UBS's involvement in major IPOs, including CATL and Heng Rui Medicine, highlights its strong position in the Hong Kong market [4] - The anticipated number of new listings in Hong Kong for 2026 is projected to reach between 150 and 200 companies, with a significant number of large-scale projects expected in the first quarter [4] Group 4 - Hu Zhizhe, President of UBS China, emphasizes Hong Kong's role as a "bridgehead" for connecting Chinese enterprises with global capital, facilitating a two-way flow of investment [4] - Hu also notes that UBS is capturing new opportunities by assisting Chinese companies in accessing international capital markets while helping global capital engage with China's growth story [4] - Recent announcements from Chinese securities firms, such as Huatai Securities and GF Securities, indicate a trend of increasing capital investment to support overseas business development [5][6]

Core Viewpoint - The report highlights the current AH premium rates of various stocks, indicating significant disparities between H-shares and A-shares, with some stocks showing extremely high premiums while others exhibit negative premiums. Group 1: Top AH Premium Rates - Northeast Electric (00042) has the highest AH premium rate at 800.00% [1] - Zhejiang Shibao (01057) follows with a premium rate of 351.95% [1] - Beijing Machinery (00187) ranks third with a premium rate of 269.91% [1] - The top ten stocks with high premium rates include companies like Hongye Futures (03678) and Sinopec Oilfield Services (01033) with premium rates of 264.44% and 263.64% respectively [2] Group 2: Bottom AH Premium Rates - Contemporary Amperex Technology (03750) has the lowest AH premium rate at -12.95% [3] - China Merchants Bank (03968) and Heng Rui Medicine (01276) follow with rates of -3.26% and -2.69% respectively [3] - Other companies in the bottom tier include Wu Chai Power (02338) and Midea Group (00300) with positive but low premiums of 7.63% and 8.11% [3] Group 3: Top Deviation Values - Andeli Juice (02218) has the highest deviation value at 28.13% [4] - Goldwind Technology (02208) and Junshi Biosciences (01877) follow with deviation values of 23.37% and 16.76% respectively [4] - Other notable companies include Beijing Machinery (00187) with a deviation value of 12.63% [4] Group 4: Bottom Deviation Values - Zhejiang Shibao (01057) has the lowest deviation value at -39.21% [5] - Northeast Electric (00042) and Yangtze Optical Fibre and Cable (06869) follow with deviation values of -38.76% and -35.09% respectively [5] - Other companies with negative deviation values include Nanhua Futures (02691) and Chenming Paper (01812) [5]

Market Performance - The Hong Kong stock market experienced fluctuations with the Hang Seng Index closing up by 361.43 points, a rise of 1.35% to 27,126.95 points [1] - The Hang Seng Tech Index increased by 28.73 points, up 0.5% to 5,754.72 points, while the National Enterprises Index rose by 97.67 points, a 1.07% increase to 9,244.88 points [1] - Major tech stocks showed mixed performance, with Alibaba up 2.85% and Tencent up 1.25%, while JD.com fell by 2.16% [1] Company News - China Power (02380.HK) reported a total electricity sales volume of 10.73105 million MWh for December 2025, a decrease of 2.31% year-on-year, with an annual total of approximately 126 million MWh, down 1.27% [2] - Harbin Electric (01133.HK) expects a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year [2] - Dongyang Sunshine Pharmaceutical (06887.HK) signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for an AI-driven drug development platform [3] - Weisheng Pharmaceutical-B (02561.HK) received approval from the National Medical Products Administration for the marketing license of its injectable growth hormone [4] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [5] - Heng Rui Pharmaceutical (01276.HK) received approval for clinical trials of its SHR-1049 injection [6] Institutional Insights - According to招商国际, the Hong Kong stock market is in a performance vacuum at the beginning of the year, with high growth expectations in the new economy driving market confidence [11] - 富国基金 suggests that the market is likely to maintain a volatile consolidation pattern, with core drivers stemming from global trade tensions and domestic economic recovery [11] - 华泰证券 emphasizes the potential for continued rebounds in the first quarter, focusing on sectors such as AI (semiconductors, software) and innovative pharmaceuticals [11] - 浙商国际 expresses optimism for sectors benefiting from policy support, including renewable energy, innovative pharmaceuticals, and AI technology [12]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1] Core Insights - The overall and weighted holdings of public funds in the pharmaceutical sector reached a new low since 2018 in Q4 2025, with the pharmaceutical heavy holdings accounting for 8.0% of all public funds, down 1.7 percentage points quarter-on-quarter [2][9] - The total scale of pharmaceutical funds in Q4 2025 was 394.6 billion yuan, a decrease of 9.2% from the previous quarter, with active pharmaceutical funds at 177.7 billion yuan, down 14% [20] - The proportion of passive pharmaceutical funds has increased significantly from 18% in Q1 2018 to 55% in Q4 2025, indicating a shift towards passive investment strategies in the sector [20] Fund Holdings Analysis - In Q4 2025, the pharmaceutical sector saw a decrease in active fund holdings, with active pharmaceutical funds accounting for 33% of the total pharmaceutical heavy holdings, up 2 percentage points, while non-pharmaceutical active funds accounted for 26%, down 5.1 percentage points [3][13] - The top five holdings by market value in public funds included Heng Rui Medicine (31.7 billion), WuXi AppTec (29.6 billion), and Innovent Biologics (16.6 billion) [6] - The top three increases in active fund holdings were for Tigermed (1.7 billion), Yimeng Biologics (1.4 billion), and CSPC Pharmaceutical Group (1.3 billion) [6] Sector-Specific Trends - The report highlights a shift in fund holdings towards innovative drugs and CXO services, while traditional Chinese medicine and high-value consumables are underweighted [6] - The report notes that the proportion of holdings in traditional Chinese medicine and biotech has increased, while holdings in BioPharma and CXO have decreased significantly [6][28] - The overall market value of holdings in the Bio-Tech sector reached 7.25% in Q4 2025, marking the highest level since Q1 2018, with active pharmaceutical funds holding 4.9% [28]

Core Viewpoint - The recent Nipah virus outbreak in India has led to increased attention and investment in the A-share pharmaceutical sector, with significant capital inflows into medical ETFs despite some declines in stock prices [1][3]. Group 1: Market Activity - The medical ETF (159929) experienced a drop of over 1% today, following a previous day of gains, but attracted 64 million yuan in capital [1]. - Over the past 10 days, the ETF has seen net inflows for 9 days, accumulating nearly 300 million yuan [1]. - Trading activity remains robust, with intraday trading volume exceeding 120 million yuan [1]. Group 2: Nipah Virus Research - The Nipah virus outbreak in West Bengal, India, has resulted in deaths and the isolation of close contacts [3]. - A significant research study published in the journal Emerging Microbes & Infections confirms that the oral nucleoside drug VV116 shows promising antiviral activity against the Nipah virus, providing new hope for treatment and prevention [3]. Group 3: Company Updates - Sanofi's (三生国健) 2025 annual performance forecast indicates a net profit of approximately 2.9 billion yuan, reflecting a year-on-year increase of 311.35%, driven by a collaboration with Pfizer [4]. - Junshi Biosciences (君实生物) has completed the issuance of its first phase of technology innovation bonds for 2026, totaling 1 billion yuan, aimed at supporting drug research and development [4]. Group 4: Sector Trends - The pharmaceutical industry is expected to benefit from a favorable investment environment and policy support, particularly for innovative drugs and technologies [6][8]. - The medical manufacturing sector has shown a slight increase in industrial value added, while revenue and profit have seen minor declines [7]. - The healthcare expenditure in China has shown a year-on-year growth of 4.7% for the first 11 months of 2025, marking a recovery after two years of decline [7]. Group 5: Investment Strategies - Investment strategies for 2026 focus on innovation, international expansion, and marginal improvements in the pharmaceutical sector [8][9]. - Key areas of interest include innovative drugs, medical devices, and the integration of new technologies such as AI and brain-machine interfaces [8][9].

Market Overview - The Hong Kong stock index showed an upward trend in early trading on January 27, with the Hang Seng Index rising by 1.07% to 27,053.05 points, the Hang Seng Tech Index increasing by 0.2% to 5,737.27 points, and the China Enterprises Index up by 0.86% to 9,225.77 points [1] - Major technology stocks exhibited mixed performance, with Alibaba up by 2.18%, Tencent Holdings up by 1.08%, JD.com down by 1.38%, and Meituan down by 0.51% [1] - Gold stocks continued to rise, with Zijin Mining and Zijin Gold International reaching historical highs, while insurance stocks were active, with AIA Group rising over 3% [1] Company News - China Power (02380.HK) reported a total electricity sales volume of 10.73105 million MWh for December 2025, a decrease of 2.31% year-on-year, with an annual cumulative total of approximately 126 million MWh, down by 1.27% year-on-year [2] - Harbin Electric (01133.HK) expects a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year [2] - Singularity National Peak (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [2] - Dongyang Sunshine Pharmaceutical (06887.HK) signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for an AI-driven drug research and development platform [3] - Vison Pharmaceutical-B (02561.HK) received approval from the National Medical Products Administration for the marketing authorization application of injectable Long-acting Growth Hormone [4] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [5] - Zhaoke Ophthalmology-B (06622.HK) is advancing the commercialization of BRIMOCHOL PF for presbyopia treatment in Singapore and Vietnam through partnerships with AFT and Qianshou [5] - Heng Rui Pharmaceutical (01276.HK) received a clinical trial approval notice for SHR-1049 injection [6] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by relevant bondholder meetings [7] - Aibo Technology Holdings (08279.HK) entered into a technical service agreement with Hong Kong Gold Trading Co., Ltd. [8] - Future Data Group (08229.HK) signed a strategic cooperation framework agreement with Linghe Culture [9] - Howey Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuan Zhi's initial public offering [10] Institutional Insights - According to招商国际, the Hong Kong stock market is currently in an earnings vacuum period, with high growth expectations for new economy sectors boosting market confidence. The appreciation of the RMB is favorable for Hong Kong stocks, and domestic policies are focusing on technological innovation and expanding domestic demand [11] - Citigroup believes that the outlook for Hong Kong stocks is better than that of A-shares, with optimism for 2026 supported by both southbound and foreign capital. However, potential risks include high overseas interest rates and corporate earnings falling short of expectations [11] - Huatai Securities noted that technology and cyclical "consumables" are expected to lead the recovery of Hong Kong stocks, with external pressures easing and domestic macro data stabilizing [11] - Guoyuan International suggests that the current environment may allow Hong Kong stocks to continue outperforming U.S. stocks, driven by low long-term valuation levels and potential recovery in domestic credit demand [12]